Avidity Biosciences ( (RNA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avidity Biosciences shares moved lower as investors reacted to shareholder approval of the company’s merger with Novartis and the planned spin-off of certain assets into a new firm, Atrium Therapeutics. The vote, held at a Feb. 26 special meeting, also included a non-binding green light for merger-related executive compensation.
Traders are now adjusting positions as options tied to Avidity stock were listed and then delisted effective Feb. 26, altering ways to hedge or speculate on the name. The restructuring and derivative changes are prompting investors to reassess the company’s future standalone value and short-term trading dynamics.
More about Avidity Biosciences
YTD Price Performance: 0.93%
Average Trading Volume: 2,461,292
Technical Sentiment Signal: Buy
Current Market Cap: $11.29B
For further insights into RNA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.